FAQ on Nutriband Inc.'s AVERSA Fentanyl Manufacturing Milestone and Price Target Increase

What is the significance of Nutriband Inc.’s recent milestone?

The completion of commercial manufacturing and scale-up for AVERSA Fentanyl marks a key inflection point, enabling Nutriband to proceed with clinical supplies production and an IND application for a Phase 1 trial.

Why was Nutriband Inc.’s price target raised to $15?

The price target was raised following the successful milestone achievement and the analyst’s positive outlook on the company’s adherence to timeline projections and avoidance of an expected equity raise.

How does the AVERSA Fentanyl patch work?

AVERSA Fentanyl is an abuse-deterrent transdermal patch that incorporates technology to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Who is involved in the development of AVERSA Fentanyl?

Nutriband Inc. is developing AVERSA Fentanyl in partnership with Kindeva, utilizing the 505(b)(2) regulatory pathway for its development.

When is the NDA submission for AVERSA Fentanyl expected?

The NDA submission is expected between late 2025 and early 2026, with full-year sales projected to begin in FY2027.

What are the projected earnings for Nutriband Inc. in FY2027?

The analyst raised the FY2027 EPS forecast to $1.57, citing the company’s progress and timeline adherence.

Where can I find more information about Nutriband Inc.?

More information is available on the company’s website at www.Nutriband.com and in the company’s newsroom at https://ibn.fm/NTRB.

What is the regulatory pathway for AVERSA Fentanyl?

AVERSA Fentanyl follows the 505(b)(2) regulatory pathway, requiring only a single Phase 1 study to show reduced appeal to recreational drug users.

How does AVERSA technology benefit the pharmaceutical industry?

AVERSA technology can be incorporated into any transdermal patch to prevent abuse and misuse of drugs with abuse potential, offering a significant advancement in drug safety.